UB Paderborn / Katalog / Suche / in CDI

OP0180 Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.130-130

2014

Volltextzugriff (PDF)

FRI0330 Safety and Efficacy of Canakinumab in Frequently Flaring Gouty Arthritis Patients Who are Contraindicated, Intolerant or Unresponsive to Non-Steroidal Anti- Inflammatory Drugs and/or Colchicine: Results from 3 Years Follow-Up

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.544-544

2015

Volltextzugriff (PDF)

AB0926 Long-Term Safety and Maintenance of Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results From a 36 Week Extension Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1209-1210

2015

Volltextzugriff (PDF)

FRI0488 A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS)

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.615-616

2016

Volltextzugriff (PDF)

FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.616

2016

Volltextzugriff (PDF)

THU0569 Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS)

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.397-398

2016

Volltextzugriff (PDF)

THU0215 Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.265-266

2016

Volltextzugriff (PDF)

FRI0528 Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.578-578

2014

Volltextzugriff (PDF)

THU0579 Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.401-402

2016

Volltextzugriff (PDF)

SAT0537 Long-Term Safety and Efficacy of Canakinumab VS Triamcinolone Acetonide in Patients with Frequent Acute Gouty Arthritis Attacks Who Are Contraindicated, Intolerant or Unresponsive to NSAIDS And/Or Colchicine

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.785-785

2014

Volltextzugriff (PDF)

AB0848 Canakinumab Pre-Filled Syringe VS Triamcinolone Acetonide in the Treatment of Acute Gouty Arthritis Attacks: Results from A Post-Hoc Analysis in Difficult-To-Treat Patients

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.1083-1083

2014

Volltextzugriff (PDF)

AB0847 Efficacy and Safety of Canakinumab Pre-Filled Syringe in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage ≥3

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.1083-1083

2014

Volltextzugriff (PDF)

OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.132-132

2014

Volltextzugriff (PDF)

FRI0496 Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis with and Without Fever

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.608-608

2015

Volltextzugriff (PDF)

AB1185 Sustained maintenance of adapted ACR pediatric response with canakinumab in patients with active systemic juvenile idiopathic arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.705-705

2013

Volltextzugriff (PDF)

AB1186 IL-1beta inhibition with canakinumab in patients with systemic juvenile idiopathic arthritis: Efficacy and safety outcomes from a single-dose, placebo-controlled study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.705-705

2013

Volltextzugriff (PDF)

The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents

International journal of clinical practice (Esher), 2010-05, Vol.64 (6), p.746-755

2010

Volltextzugriff (PDF)

THU0328 Changes in health-related quality of life in systemic juvenile idiopathic arthritis patients after single dose of canakinumab

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.266-267

2013

Volltextzugriff (PDF)

THU0477 Canakinumab Improves Health-Related Quality of Life (HRQOL) and Daily Functioning in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A325-A326

2013

Volltextzugriff (PDF)

REMIBRUTINIB DID NOT IMPACT ON TOTAL SERUM IMMUNOGLOBULIN LEVELS OF PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA

Annals of allergy, asthma, & immunology, 2023-11, Vol.131 (5), p.S31-S31

2023

Volltextzugriff (PDF)

OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A97-A98

2013

Volltextzugriff (PDF)

REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS WITH LOW OR HIGH IGE

Annals of allergy, asthma, & immunology, 2022-11, Vol.129 (5), p.S31-S32

2022

Volltextzugriff (PDF)

AB1182 Efficacy and safety of canakinumab, fully human anti-interleukin-1beta antibody, in systemic juvenile idiopathic arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.705-705

2013

Volltextzugriff (PDF)

REMIBRUTINIB TREATMENT IMPROVES HIVE SEVERITY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS

Annals of allergy, asthma, & immunology, 2023-11, Vol.131 (5), p.S11-S11

2023

Volltextzugriff (PDF)

REMIBRUTINIB TREATMENT IMPROVES SLEEP AND ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: PHASE 2B STUDY RESULTS

Annals of allergy, asthma, & immunology, 2022-11, Vol.129 (5), p.S32-S32

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

OP0180 Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients

FRI0330 Safety and Efficacy of Canakinumab in Frequently Flaring Gouty Arthritis Patients Who are Contraindicated, Intolerant or Unresponsive to Non-Steroidal Anti- Inflammatory Drugs and/or Colchicine: Results from 3 Years Follow-Up

AB0926 Long-Term Safety and Maintenance of Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results From a 36 Week Extension Study

FRI0488 A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS)

FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes

THU0569 Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS)

THU0215 Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial

FRI0528 Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome

THU0579 Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial

SAT0537 Long-Term Safety and Efficacy of Canakinumab VS Triamcinolone Acetonide in Patients with Frequent Acute Gouty Arthritis Attacks Who Are Contraindicated, Intolerant or Unresponsive to NSAIDS And/Or Colchicine

AB0848 Canakinumab Pre-Filled Syringe VS Triamcinolone Acetonide in the Treatment of Acute Gouty Arthritis Attacks: Results from A Post-Hoc Analysis in Difficult-To-Treat Patients

AB0847 Efficacy and Safety of Canakinumab Pre-Filled Syringe in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage ≥3

OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients

FRI0496 Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis with and Without Fever

AB1185 Sustained maintenance of adapted ACR pediatric response with canakinumab in patients with active systemic juvenile idiopathic arthritis

AB1186 IL-1beta inhibition with canakinumab in patients with systemic juvenile idiopathic arthritis: Efficacy and safety outcomes from a single-dose, placebo-controlled study

The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents

THU0328 Changes in health-related quality of life in systemic juvenile idiopathic arthritis patients after single dose of canakinumab

THU0477 Canakinumab Improves Health-Related Quality of Life (HRQOL) and Daily Functioning in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients

REMIBRUTINIB DID NOT IMPACT ON TOTAL SERUM IMMUNOGLOBULIN LEVELS OF PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA

OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial

REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS WITH LOW OR HIGH IGE

AB1182 Efficacy and safety of canakinumab, fully human anti-interleukin-1beta antibody, in systemic juvenile idiopathic arthritis

REMIBRUTINIB TREATMENT IMPROVES HIVE SEVERITY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS

REMIBRUTINIB TREATMENT IMPROVES SLEEP AND ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: PHASE 2B STUDY RESULTS

Suchergebnisse filtern